New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
05:55 EDTBSX, BSX, BSX, BSX, RNST, RNST, RNST, RNST, HBHC, HBHC, HBHC, HBHC, IBKC, IBKC, IBKC, IBKC, HOMB, HOMB, HOMB, HOMB, SFNC, SFNC, SFNC, SFNC, OZRK, OZRK, OZRK, OZRK, PNFP, PNFP, PNFP, PNFP, UCBI, UCBI, UCBI, UCBIStephens to host a field trip
Bank Field Trip travels through Memphis, New Orleans, Little Rock, Nashville and Atlanta on February 19-22.
News For BSX;RNST;HBHC;IBKC;HOMB;SFNC;OZRK;PNFP;UCBI From The Last 14 Days
Check below for free stories on BSX;RNST;HBHC;IBKC;HOMB;SFNC;OZRK;PNFP;UCBI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 19, 2014
10:06 EDTUCBI, IBKCOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:25 EDTIBKCIBERIABANK downgraded to Market Perform from Outperform at Raymond James
Subscribe for More Information
08:24 EDTUCBIUnited Community Banks downgraded to Outperform from Strong Buy at Raymond James
Subscribe for More Information
September 17, 2014
10:00 EDTOZRKOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AB InBev (BUD) upgraded to Hold from Sell at Societe Generale... Baker Hughes (BHI) upgraded to Outperform from Sector Perform at Howard Weil... Bank of the Ozarks (OZRK) upgraded to Buy from Hold at BB&T... Bill Barrett (BBG) upgraded to Buy from Neutral at Mizuho... Cepheid (CPHD) upgraded to Buy from Hold at Cantor... Cigna (CI) upgraded to Positive from Neutral at Susquehanna... Extra Space Storage (EXR) upgraded to Buy from Hold at Jefferies... GNC Holdings (GNC) upgraded to Outperform from Neutral at Wedbush... MB Financial (MBFI) upgraded at DA Davidson... Mondelez (MDLZ) upgraded to Buy from Hold at Societe Generale... Radian Group (RDN) upgraded to Buy from Neutral at Compass Point... Skullcandy (SKUL) assumed with a Overweight from Neutral at Piper Jaffray... Under Armour (UA) upgraded to Overweight from Neutral at Piper Jaffray.
07:43 EDTBSXBofA/Merrill to hold a conference
Subscribe for More Information
07:34 EDTOZRKBank of the Ozarks upgraded to Buy from Hold at BB&T
07:28 EDTRNST, SFNC, OZRK, HOMBStephens to hold a forum
4th Annual Bank CEO Forum to be held in Little Rock, Arkansas on September 17-18.
05:09 EDTBSXBoston Scientific receives CE Mark for Vercise DBS system
Subscribe for More Information
September 16, 2014
07:58 EDTBSXBoston Scientific product still likely to get nod despite data, says Wells Fargo
Although new data presented at TCT showed that the confirmatory PREVAIL study of Boston Scientific's Watchman device missed both co-primary efficacy endpoints, Wells Fargo still thinks there is a 60%-70% chance of an FDA panel recommending approval of the device on October 8. Wells keeps an Outperform rating on the stock.
07:43 EDTHOMB, HBHCRBC Capital to hold a conference
Subscribe for More Information
September 15, 2014
16:08 EDTBSXBoston Scientific says REPRISE II data show sustained safety, performance
New data from the Boston Scientific clinical trial program of the LotusValve System continue to demonstrate strong performance as a less invasive treatment for patients with severe aortic stenosis who are considered high risk for surgical valve replacement. Data from the REPRISE II clinical trial confirmed safety and effectiveness out to one year, with more than 86% of patients exhibiting a complete absence of paravalvular aortic regurgitation and no patients demonstrating moderate or severe paravalvular aortic regurgitation. New data from the REPRISE I and REPRISE II clinical trials were presented at the 26th Transcatheter Cardiovascular Therapeutics meeting, the annual scientific symposium of the Cardiovascular Research Foundation. REPRISE II is an ongoing prospective, single-arm, multi-center study designed to evaluate safety and performance of the Lotus Valve System for symptomatic patients with severe calcific aortic stenosis who are considered high risk for surgical valve replacement. The study enrolled 120 patients at 14 sites in Australia, France, Germany and the UK. In REPRISE II, key one-year results include the following: Mean aortic valve pressure gradient remained low and stable at 12.6 + 5.7 mmHg. More than 86% of patients had no paravalvular aortic regurgitation by independent core lab assessment. In addition, no cases of moderate or severe paravalvular aortic regurgitation occurred. Mild and trace paravalvular aortic regurgitation rates were low at 11.4 and 2.3%, respectively. Cardiovascular mortality rate was 6.7%. Disabling stroke rate was 3.4%. No cases of non-study valve implantation, unplanned use of cardiopulmonary bypass, valve embolization, valve-in-valve or ectopic valve placement occurred.
07:45 EDTBSXCardiovascular Research Foundation to hold a conference
Transcatheter Cardiovascular Therapeutics: TCT 2014 to be held in Washington, D.C. on September 13-17 with some presentations being webcasted. Webcast Link
September 12, 2014
15:03 EDTBSXSt. Jude Medical pausing Portico sales, implants, says Wells Fargo
Subscribe for More Information
September 8, 2014
07:26 EDTBSXMorgan Stanley to hold a conference
Subscribe for More Information
07:04 EDTBSXBoston Scientific sell-off overdone, says RBC Capital
RBC Capital said the sell-off in Boston Scientific is overdone and that upcoming catalysts will reverse sentiment. The firm would be aggressive buyers ahead of the October 8 FDA Watchman panel and the release of pivotal Synergy data on November 19 AHA meeting. Shares are Outperform rated with a $15 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use